Apellis Pharmaceuticals, Inc.

APLSDelisted May 14, 2026

Industry: Pharmaceutical Preparations
SEC CIK: 0001492422

SEC filings (opens in a new tab)

Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 324; Q1 2026, +49 vs. previous quarter
13F value: $5.56B; Reported value at the end of Q1 2026
Superinvestors holding: 1; At the end of Q1 2026

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2025: $1.00B; +28.5% year over year
Net income, FY2025: $22.4M; No comparable prior period
Free cash flow, FY2025: $45.0M; No comparable prior period
Revenue, Q1 FY2026: $268.3M; +60.9% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Apr 30, 2026.

Short interest: 10.8M; Shares sold short
Change: −3.49M; −24.5% vs. previous
Days to cover: 3.06; At average daily volume

Superinvestors holding APLS, Q1 2026

Go to the superinvestors tab

1 superinvestor reports holding Apellis Pharmaceuticals, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

0.6%

Apellis Pharmaceuticals, Inc.'s share of the portfolio

Shares: 1,056,000
Value: $42.5M

Latest insider trades

See all insider trades

Open-market purchases and sales by Apellis Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change
Feb 13, 2026 (view filing)	Feb 11	2 days	DeLong Mark JeffreyChief Business & Strat Officer	SSale	−368	$22.15	−$8.15K	−0.3%114.6K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Baumal CarolineChief Medical Officer	SSale	−2.80K	$21.77	−$60.9K	−3.1%86.5K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Chopas James GeorgeVP/Chief Accounting Officer	SSale	−2.06K	$21.77	−$44.9K	−4.0%49.8K after
Jan 23, 2026 (view filing)	Jan 22	1 day	DeLong Mark JeffreyChief Business & Strat Officer	SSale	−3.37K	$21.77	−$73.4K	−4.1%78.4K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Deschatelets PascalChief Scientific Officer	SSale	−5.93K	$21.77	−$129.1K	−0.5%1.15M after
Jan 23, 2026 (view filing)	Jan 22	1 day	Francois CedricChief Executive Officer	SSale	−27.2K	$21.77	−$592.0K	−8.7%286.0K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Nicholson NurChief Technical Officer	SSale	−7.72K	$21.77	−$168.2K	−9.8%71.1K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Sullivan Timothy EugeneChief Financial Officer	SSale	−10.3K	$21.77	−$223.9K	−9.9%93.9K after
Jan 23, 2026 (view filing)	Jan 22	1 day	Watson David O.General Counsel	SSale	−7.83K	$21.77	−$170.5K	−8.1%88.5K after
Jan 21, 2026 (view filing)	Jan 20	1 day	Baumal CarolineChief Medical Officer	SSale	−1.88K	$19.79	−$37.2K	−2.1%89.3K after

Top 10 13F holders, Q1 2026

See all 324 holders

The largest institutional positions in Apellis Pharmaceuticals, Inc. at the end of Q1 2026; share changes are against Q4 2025.

Institutions holding APLS in Q1 2026
Institution	Shares	Value	% of portfolio	Change in shares	Action
BlackRock, Inc.	13,536,964	$544.6M	0.01%	+7,276,851+116.2%	Added
Avoro Capital Advisors LLC	12,222,222	$491.7M	4.84%	00.0%	Unchanged
Morgan Stanley	10,042,399	$404.0M	0.02%	+869,395+9.5%	Added
State Street Corp	6,844,990	$275.4M	0.01%	+2,231,544+48.4%	Added
UBS Group AG	6,206,681	$249.7M	0.04%	+2,020,459+48.3%	Added
Vanguard Portfolio Management LLC	5,404,559	$217.4M	0.01%	+5,404,559	New
Pentwater Capital Management LP	5,250,000	$211.2M	1.50%	+5,250,000	New
Vanguard Capital Management LLC	4,768,944	$191.9M	0.00%	+4,768,944	New
Deep Track Capital, LP	4,532,374	$182.3M	3.76%	−3,217,626−41.5%	Reduced
Point72 Asset Management, L.P.	4,183,918	$168.3M	0.29%	+3,586,246+600.0%	Added

Holders of 5% or more of APLS

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Apellis Pharmaceuticals, Inc..

Largest holders of APLS from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
BlackRock, Inc.	13G	10.50%13.2M shares	+6.00 ppfrom 4.50%	Oct 18, 20244 filings	Feb 6, 2026	SEC
State Street Corp	13G	5.40%6.85M shares	New	May 12, 20261 filing	May 12, 2026	SEC